News | March 19, 2009

Drug Information Association Hosts Conference on Cardiovascular Safety, QT/Arrhythmia Assessment in Drug Development

March 19, 2009 - The Drug Information Association (DIA), in cooperation with the Heart Rhythm Society (HRS) and the FDA, will host Cardiovascular Safety and QT/Arrhythmia Assessment in Drug Development: Optimizing Drug Development Wednesday, April 29 – Friday, May 1 in Bethesda, MD.

Regulatory, industry, and scientific leaders from around the world will convene to discuss the evolution of drug development, cardiac repolarization, and cardiovascular (CV) safety. The conference will present basic concepts related to the collection, analysis, and interpretation of clinical ECG data, taking into consideration the effect of study design and conduct on these parameters. Sessions will also cover strategies to design a program for QT assessment in all stages of clinical trials and best practices for designing, conducting, analyzing, and interpreting data from a thorough QT/QTc study.

Speakers will also address the strategy behind choosing the optimal timing of the thorough QT study, underlying regulatory thinking in terms of QT prolongation and patient safety, relevant clinical, technological, and statistical issues in the assessment of QT/QTc prolongation in clinical trials. The conference will also address emerging concepts and technologies for QT assessment, such as highly automated measurement methods and their potential role.

"This open forum will discuss the new direction in the development of pharmaceutical agents, practical challenges and possible solutions, ways of challenging the current science, and regulatory approaches,” explains Program Chair Philip Sager, M.D., FACC, FHRS, chief medical officer, CardioDx Inc.

DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and Webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.

For more information: www.diahome.org

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Overlay Init